Fig. 3From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiativeSequencing of treatment in patients diagnosed with stage IIIB–IV NSCLC in 2015–2016 with NSQ (a) or SQ (b). NSCLC non-small cell lung cancer, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma, LoT line of therapy, MAB monoclonal antibody, TKI tyrosine kinase inhibitor, DoT duration of therapy, IQR interquartile range, TTNT time from SACT initiation to next treatment or death, NA not available, NE not evaluableBack to article page